Assessing Everolimus in Fist Line Treatment on Patients With Metastatic Kidney Cancer
Status:
Terminated
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
It is a an open label, multicentric, phase II study assessing the efficacy of everolimus
(given per os) as a first line treatment in kidney cancer of bad prognosis.
92 patients will be included (anticipated). The treatment by everolimus will continue until
progression, significant toxicity or withdraw of consent